drugset / Trial / NCT06175780
Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This dose escalation and dose expansion study is to evaluate and characterize the tolerability, safety, pharmacokinetics and efficacy profile of single agent KY-0118 in Locally Advanced or Metastatic Solid Tumor Patients.
Timeline
- Start
- 2022-12-28
- Primary completion
- 2025-12-28
- Completion
- 2025-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KY-0118 | Unknown | 0.3 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 1 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 3 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 6 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 12 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 24 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 36 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 48 ug/kg | Intravenous |
| Subject | KY-0118 | Unknown | 64 ug/kg | Intravenous |